AbbVie (ABBV) : The total money flow in AbbVie (ABBV) was negative ($10.62 million), which signals selling by the traders on Mondays session. They trimmed their holdings by selling the stock on downticks to the tune of $69.03 million. In comparison, the inflow of money into the stock on upticks was $58.4 million. The uptick to downtick ratio was 0.85. Similarly, the block trades show selling by large traders on strength. The value of stocks sold down on downtick was $23.78 million. The value of transactions on uptick was $9.08 million. The negative money flow of ($14.7 million) confirms the selling in AbbVie (ABBV) on strength. The uptick to downtick ratio of block trades was 0.38. AbbVie (ABBV) gained $0.2 at $67.39, a gain of 0.3% over the previous days close. However, the stock registered 1.28% in the week.
Shares of AbbVie Inc. rose by 1.58% in the last five trading days and 6.43% for the last 4 weeks. AbbVie Inc. is up 8.86% in the last 3-month period. Year-to-Date the stock performance stands at 17.08%.
AbbVie (NYSE:ABBV): During Mondays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $67.47 and $67.32 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $68.12. The buying momentum continued till the end and the stock did not give up its gains. It closed at $67.39, notching a gain of 0.30% for the day. The total traded volume was 5,215,360 . The stock had closed at $67.19 on the previous day.
In a related news, The Securities and Exchange Commission has divulged that Schumacher Laura J, Officer (Executive Vice President) of AbbVie Inc., had unloaded 186,106 shares at an average price of $60.07 in a transaction dated on June 24, 2016. The total value of the transaction was worth $11,179,387.
AbbVie Inc. (AbbVie) is a global, research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Companys products are focused on treating conditions, such as chronic autoimmune diseases, including rheumatoid arthritis, psoriasis and Crohns disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinsons disease; complications associated with chronic kidney disease and cystic fibrosis, and other health conditions, such as low testosterone. AbbVie also has a pipeline of new medicines, including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties, such as immunology, virology/liver disease, oncology, renal disease, neurological diseases and womens health. The Companys product portfolio includes HUMIRA, HCV products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.